Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats

European Neuropsychopharmacology

Volumn 20, Issue 1, 2010, Pages 25-36

  Spano, Maria Sabrina ^a   Fadda, Paola ^a   Frau, Roberto ^a   Fattore, Liana ^a,b   Fratta, Walter ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

Cannabinoid self administration; Cognitive deficit; PCP; Prepulse inhibition; Schizophrenia; Social interaction

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; PHENCYCLIDINE;

ACOUSTIC REFLEX; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; STARTLE REFLEX;

ACOUSTIC STIMULATION; ANIMALS; BENZOXAZINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; INTERPERSONAL RELATIONS; MALE; MORPHOLINES; NAPHTHALENES; NEURAL INHIBITION; PHENCYCLIDINE; PSYCHOMOTOR PERFORMANCE; RATS; RECEPTORS, CANNABINOID; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SELF ADMINISTRATION; STARTLE REACTION; STATISTICS, NONPARAMETRIC;

EID: 71549147546     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.09.004     Document Type: Article

References (93)

1. Allison K.R., and Dignam C. Social and school factors in predicting cannabis use among Ontario high school students. Can. J. Public Health 81 (1990) 301-306
2. Anokhin A.P., Heath A.C., Myers E., Ralano A., and Wood S. Genetic influences on prepulse inhibition of startle reflex in humans. Neurosci. Lett. 353 (2003) 45-48
3. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325 (2002) 1212-1213
4. Bakshi V.P., and Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122 (1995) 198-201
5. Barnes T.R., Mutsatsa S.H., Hutton S.B., Watt H.C., and Joyce E.M. Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiatry 188 (2006) 237-242
6. Bolla K.I., Brown K., Eldreth D., Tate K., and Cadet J.L. Dose-related neurocognitive effects of marijuana use. Neurology 59 (2002) 1337-1343
7. Bortolato M., Aru G.N., Frau R., Orrù M., Luckey G.C., Boi G., and Gessa G.L. The CB receptor agonist WIN55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology 177 (2005) 264-271
8. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., and Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of delta9-tetrahydrocannabinol. Psychopharmacology 192 (2007) 325-336
9. Boys A., Marsden J., and Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ. Res. 16 (2001) 457-469
10. Braff D.L., and Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47 (1990) 181-188
11. Braff D.L., and Light G.A. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin. Neurosci. 7 (2005) 125-135
12. Braff D.L., Swerdlow N.R., and Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 156 (1999) 596-602
13. Cadenhead K.S., Swerdlow N.R., Shafer K.M., Diaz M., and Braff D.L. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am. J. Psychiatry 157 (2000) 1660-1668
14. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., and Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 265-275
15. Crespo-Facorro B., Wiser A.K., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study. Hum. Brain Mapp. 12 (2001) 219-231
16. Cutler M.G., and Mackintosh J.H. Cannabis and delta-9-tetrahydrocannabinol. Effects on elements of social behaviour in mice. Neuropharmacology 23 (1984) 1091-1097
17. Dean B., Sundram S., Bradbury R., Scarr E., and Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103 (2001) 9-15
18. Degenhardt L., Hall W., and Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 71 (2003) 37-48
19. Deiana S., Fattore L., Spano M.S., Cossu G., Porcu E., Fadda P., and Fratta W. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology 52 (2007) 646-654
20. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., and Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 19 (2003) 2-5
21. Dissanayake D.W., Zachariou M., Marsden C.A., and Mason R. Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55, 212-2. Neuropharmacology 55 (2008) 1397-1404
22. Dixon L., Haas G., Weiden P.J., Sweeney J., and Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 148 (1991) 224-230
23. Doniger G.M., Silipo G., Rabinowicz E.F., Snodgrass J.G., and Javitt D.C. Impaired sensory processing as a basis for object-recognition deficits in schizophrenia. Am. J. Psychiatry 158 (2001) 1818-1826
24. D'Souza D.C. Cannabinoids and psychosis. Int. Rev. Neurobiol. 78 (2007) 289-326
25. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., and Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57 (2005) 594-608
26. Egerton A., Reid L., McGregor S., Cochran S.M., Morris B.J., and Pratt J.A. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 198 (2008) 37-49
27. Eggan S.M., Hashimoto T., and Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 65 (2008) 772-784
28. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., Gigerenzer G., and Hoehe M.R. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142 (1999) 295-301
29. Ellenbroek B.A., and Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav. Pharmacol. 11 (2000) 223-233
30. Ennaceur A., and Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 31 (1988) 47-59
31. Fadda P., Scherma M., Spano M.S., Salis P., Melis V., Fattore L., and Fratta W. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. NeuroReport 17 (2006) 1629-1632
32. Fattore L., Cossu G., Martellotta C.M., and Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN55,212-2 in rats. Psychopharmacology 156 (2001) 410-416
33. Fattore L., Spano M.S., Altea S., Angius F., Fadda P., and Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br. J. Pharmacol. 152 (2007) 795-804
34. Foltin R.W., and Fischman M.W. Effects of smoked marijuana on human social behavior in small groups. Pharmacol. Biochem. Behav. 30 (1988) 539-541
35. Foltin R.W., Brady J.V., Fischman M.W., Emurian C.S., and Dominitz J. Effects of smoked marijuana on social interaction in small groups. Drug Alcohol Depend. 20 (1987) 87-93
36. Genn R.F., Tucci S., Marco E.M., Viveros M.P., and File S.E. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55, 940 in the social interaction test. Pharmacol. Biochem. Behav. 77 (2004) 567-573
37. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., and Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
38. Graham F.K. The more or less startling effects of weak prestimulation. Psychophysiology 12 (1975) 238-248
39. Grayson B., Idris N.F., and Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 184 (2007) 31-38
40. Heckers S., Curran T., Goff D., Rauch S.L., Fischman A.J., Alpert N.M., and Schacter D.L. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol. Psychiatry 48 (2000) 651-657
41. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., and van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330 (2005) 11-14
42. Herkenham M., Lynn A.B., de Costa B.R., and Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547 (1991) 267-274
43. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
44. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
45. Jockers-Scherübl M.C., Wolf T., Radzei N., Schlattmann P., Rentzsch J., Gómez-Carrillo de Castro A., and Kühl K.P. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 1054-1063
46. Kovasznay B., Fleischer J., Tanenberg-Karant M., Jandorf L., Miller A.D., and Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr. Bull. 23 (1997) 195-201
47. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., and Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 7 (1999) 125-143
48. Kumari V., Fannon D., Ffytche D.H., Raveendran V., Antonova E., Premkumar P., Cooke M.A., Anilkumar A.P., Williams S.C., Andrew C., Johns L.C., Fu C.H., McGuire P.K., and Kuipers E. Functional MRI of Verbal Self-Monitoring in Schizophrenia: Performance and Illness-Specific Effects. Schizophr. Bull. (2008) (Nov 7 [Electronic publication ahead of print])
49. Lahti A.C., and Tamminga C.A. Recent developments in the neuropharmacology of schizophrenia. Am. J. Health Syst. Pharm. 52 (1995) S5-8
50. Leroy S., Griffon N., Bourdel M.C., Olié J.P., Poirier M.F., and Krebs M.O. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet. 105 (2001) 749-752
51. Leweke F.M., and Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict. Biol. 13 (2008) 264-275
52. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., and Piomelli D. Elevated endogenous cannabinoids in schizophrenia. NeuroReport 10 (1999) 1665-1669
53. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., Neatby M.A., Schneider M., Gerth C.W., Hellmich M., Klosterkötter J., and Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 94 (2007) 29-36
54. Long L.E., Malone D.T., and Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31 (2006) 795-803
55. Malone D.T., and Taylor D.A. The effect of delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav. Brain Res. 166 (2006) 101-109
56. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5 (2005) 101-106
57. Müller-Vahl K.R., and Emrich H.M. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev. Neurother. 8 (2008) 1037-1048
58. Newell K.A., Deng C., and Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 172 (2006) 556-560
59. Ogborne A.C., Smart R.G., Weber T., and Birchmore-Timney C. Who is using cannabis as a medicine and why: an exploratory study. J. Psychoactive Drugs 32 (2000) 435-443
60. O'Shea M., McGregor I.S., and Mallet P.E. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar long lasting deficits in object recognition and reduced social interaction in rats. J. Psychopharmacol. 20 (2006) 611-621
61. Pencer A., and Addington J. Substance use and cognition in early psychosis. J. Psychiatry Neurosci. 28 (2003) 48-54
62. Perry W., and Braff D.L. Information-processing deficits and thought disorder in schizophrenia. Am. J. Psychiatry 151 (1994) 363-367
63. Pope Jr. H.G., Gruber A.J., Hudson J.I., Huestis M.A., and Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry 58 (2001) 909-915
64. Potvin S., Joyal C.C., Pelletier J., and Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr. Res. 100 (2008) 242-251
65. Quednow B.B., Kühn K.U., Hoenig K., Maier W., and Wagner M. Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 29 (2004) 982-990
66. Reichenberg A. Cognitive impairment as a risk factor for psychosis. Dialogues Clin. Neurosci. 7 (2005) 31-38
67. Rentzsch J., Penzhorn A., Kernbichler K., Plöckl D., Gómez-Carrillo de Castro A., Gallinat J., and Jockers-Scherübl M.C. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Exp. Neurol. 205 (2007) 241-249
68. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6 (1995) 55-65
69. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7 (1996) 3-23
70. Schaub M., Fanghaenel K., Senn C., and Stohler R. Cannabis using schizophrenia patients treated with atypical neuroleptics: do their symptoms differ from those of cannabis abstainers?. Subst. Use Misuse 43 (2008) 2045-2052
71. Schneider M., and Koch M. The cannabinoid agonist WIN55,212-2 reduces sensorimotor gating and recognition memory in rats. Behav. Pharmacol. 13 (2002) 29-37
72. Schneider M., and Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28 (2003) 1760-1769
73. Schneider M., Drews E., and Koch M. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2. Behav. Pharmacol. 16 (2005) 447-454
74. Schneider M., Schömig E., and Leweke F.M. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict. Biol. 13 (2008) 345-357
75. Schnell T., Koethe D., Daumann J., and Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology 205 (2009) 45-52
76. Schwarcz G., Karajgi B., and McCarthy R. Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J. Clin. Psychopharmacol. 29 (2009) 255-258
77. Seifert J., Ossege S., Emrich H.M., Schneider U., and Stuhrmann M. No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci. Lett. 426 (2007) 29-33
78. Sethi B.B., Trivedi J.K., Kumar P., Gulati A., Agarwal A.K., and Sethi N. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors. Biol. Psychiatry 21 (1986) 3-10
79. Sewell R.A., Ranganathan M., and D'Souza D.C. Cannabinoids and psychosis. Int. Rev. Psychiatry 21 (2009) 152-162
80. Snyder S.H. Phencyclidine. Nature 285 (1980) 355-356
81. Stanley-Cary C.C., Harris C., and Martin-Iverson M.T. Differing effects of the cannabinoid agonist, CP 55, 940, in an alcohol or Tween 80 solvent, on prepulse inhibition of the acoustic startle reflex in the rat. Behav. Pharmacol. 13 (2002) 15-28
82. Steinpreis R.E., Sokolowski J.D., Papanikolaou A., and Salamone J.D. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol. Biochem. Behav. 47 (1994) 579-585
83. Stirling J., Lewis S., Hopkins R., and White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 75 (2005) 135-137
84. Strous R.D., Alvir J.M., Robinson D., Gal G., Sheitman B., Chakos M., and Lieberman J.A. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr. Bull. 30 (2004) 265-278
85. Swerdlow N.R., Braff D.L., Taaid N., and Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 51 (1994) 139-154
86. Turetsky B.I., Kohler C.G., Indersmitten T., Bhati M.T., Charbonnier D., and Gur R.C. Facial emotion recognition in schizophrenia: when and why does it go awry?. Schizophr. Res. 94 (2007) 253-263
87. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., Fujiwara Y., Sakai A., and Kuroda S. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 7 (2002) 515-518
88. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., and Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 156 (2002) 319-327
89. Walter H., Ciaramidaro A., Adenzato M., Vasic N., Ardito R.B., Erk S., and Bara B.G. Dysfunction of the social brain in schizophrenia is modulated by intention type: an fMRI study. Soc. Cogn. Affect Neurosci. 4 (2009) 166-176
90. Wegener N., Kuhnert S., Thüns A., Roese R., and Koch M. Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. Psychopharmacology 198 (2008) 375-385
91. Wegener N., and Koch M. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res. 1253 (2009) 81-91
92. Wobrock T., and Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder-reviewing the evidence and clinical recommendations. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1375-1385
93. Zavitsanou K., Garrick T., and Huang X.F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 355-360